Impact of co-mutations and transcriptional signatures in non-small cell lung cancer patients treated with adagrasib in the KRYSTAL-1 trial.

导出 LinkOut

翻译打印收藏纠错

第一作者： Marcelo V,Negrao

第一单位： The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

作者： Marcelo V,Negrao ^[1] ; Alvaro G,Paula ^[1] ; David,Molkentine ^[1] ; Laura,Hover ^[2] ; Monique,Nilsson ^[1] ; Natalie,Vokes ^[1] ; Lars,Engstrom ^[3] ; Andrew,Calinisan ^[3] ; David M,Briere ^[3] ; Laura,Waters ^[4] ; Jill,Hallin ^[3] ; Lixia,Diao ^[5] ; Mehmet,Altan ^[1] ; George R,Blumenschein ^[1] ; Ferdinandos,Skoulidis ^[1] ; Jing,Wang ^[6] ; Scott E,Kopetz ^[7] ; David S,Hong ^[8] ; Don L,Gibbons ^[1] ; Peter,Olson ^[3] ; James G,Christensen ^[3] ; John V,Heymach ^[1]

作者单位： The University of Texas MD Anderson Cancer Center, Houston, TX, United States. ^[1] Monoceros Biosciences, LLC, San Diego, CA, United States. ^[2] Mirati Therapeutics (United States), San Diego, CA, United States. ^[3] Mirati Therapeutics, San Diego, CA, United States. ^[4] The University of Texas MD Anderson Cancer Center, Houston, United States. ^[5] The University of Texas MD Anderson Cancer Center, ´Houston, TX, United States. ^[6] University of Texas MD Anderson Cancer Center, Houston, TX, United States. ^[7] The University of Texas MD Anderson Cancer Center, Houston, Texas, United States. ^[8]

DOI 10.1158/1078-0432.CCR-24-2310

PMID 39804166

发布时间 2025-01-13

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Clinical cancer research

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Impact of co-mutations and transcriptional signatures in non-small cell lung cancer patients treated with adagrasib in the KRYSTAL-1 trial.

Clinical cancer research

相似文献

Clinical cancer research

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Impact of co-mutations and transcriptional signatures in non-small cell lung cancer patients treated with adagrasib in the KRYSTAL-1 trial.

Clinical cancer research

相似文献

Clinical cancer research

相关期刊

检索历史清除